Mitapivat
Agios Pharmaceuticals
[]
very exciting early dose finding period results of phase ii #mitapivat study in #sicklecelldisease improving hb, reducing haemolysis &amp; altering point of sickling #eha2022 #vienna 
Haematologist, red cell disorders and marrow failure. Working towards definitive cure: #BMT #genetherapy. @ImperialNHS @ImperialImmuno @TheEBMT @ApothecariesLDN